MLTX,IRWD Stock Price and Quote

Dollar change -1.09
Percentage change -2.01	%

Peers: AMGN VRTX REGN ALNY BIIB BMRN GILD INCY SRPT BLUE

| Held by: FBCG VHT SBIO NUSC ESML ONEQ VT MSSM TMSL GURU

Index	-	P/E	-	EPS (ttm)	-2.30	Insider Own	16.60%	Shs Outstand	63.47M	Perf Week	8.35%
Market Cap	3.41B	Forward P/E	-	EPS next Y	-3.64	Insider Trans	-0.22%	Shs Float	52.94M	Perf Month	23.47%
Enterprise Value	3.01B	PEG	-	EPS next Q	-0.72	Inst Own	94.43%	Short Float	11.47%	Perf Quarter	43.60%
Income	-145.21M	P/S	-	EPS this Y	-51.57%	Inst Trans	-10.35%	Short Ratio	11.62	Perf Half Y	20.74%
Sales	0.00M	P/B	8.27	EPS next Y	-27.06%	ROA	-27.01%	Short Interest	6.07M	Perf YTD	-1.96%
Book/sh	6.42	P/C	7.10	EPS next 5Y	-26.36%	ROE	-30.57%	52W High	58.26 -8.87%	Perf Year	5.78%
Cash/sh	7.48	P/FCF	-	EPS past 3/5Y	34.85% -319.65%	ROIC	-30.15%	52W Low	31.42 68.97%	Perf 3Y	883.15%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.35% 3.95%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-206.92%	Oper. Margin	-	ATR (14)	2.07	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	21.11	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	67.35	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	21.11	EPS Q/Q	-189.37%	SMA20	9.74%	Beta	1.27	Target Price	79.13
Payout	-	Debt/Eq	0.19	Sales Q/Q	-	SMA50	19.81%	Rel Volume	0.70	Prev Close	54.18
Employees	100	LT Debt/Eq	0.18	Earnings	May 12 AMC	SMA200	17.02%	Avg Volume	522.41K	Price	53.09
IPO	Oct 20, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	16.43% -	Trades		Volume	363,199	Change	-2.01%

Date	Action	Analyst	Rating Change	Price Target Change
May-19-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$61
Mar-18-25	Initiated	RBC Capital Mkts	Outperform	$67
Jan-17-25	Upgrade	Goldman	Neutral → Buy	$62 → $82
Nov-05-24	Resumed	Wedbush	Outperform	$92 → $73
Aug-26-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-25-24	Initiated	Oppenheimer	Outperform	$104
Apr-02-24	Initiated	Goldman	Neutral	$62
Feb-15-24	Initiated	Wolfe Research	Outperform	$77
Dec-08-23	Initiated	Citigroup	Buy	$72
Nov-02-23	Initiated	Stifel	Buy	$74
Sep-14-23	Downgrade	Bryan Garnier	Buy → Neutral
Aug-31-23	Initiated	Needham	Buy	$76
Jun-15-23	Initiated	Barclays	Equal Weight	$28
May-01-23	Initiated	Guggenheim	Buy	$51
Mar-22-23	Initiated	Wedbush	Outperform	$33
Mar-09-23	Initiated	BTIG Research	Buy	$36
Feb-14-23	Initiated	Cantor Fitzgerald	Overweight	$23
Feb-02-23	Initiated	Bryan Garnier	Buy	$22
Nov-11-22	Initiated	Jefferies	Buy	$16
Aug-25-22	Initiated	SVB Leerink	Outperform	$17

Show Previous Ratings

Jul-09-25 01:09AM	Merck nears about $10 billion deal for London-based lung therapy firm Verona, FT reports (Reuters)
Jun-04-25 12:06PM	MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout (Zacks) +5.15%
Jun-03-25 09:33AM	Constellation and Meta, Merck, Snowflake: Trending Tickers (Yahoo Finance Video) +17.95%
09:32AM	MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover (Investor's Business Daily)
09:27AM	MoonLake Immunotherapeutics Catapults On Rumored $3 Billion Merck Takeover Bid (Investor's Business Daily)
07:38AM	Loading…
07:38AM	Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report (Benzinga)
07:20AM	MoonLake Stock Jumps 23%. Why a $3 Billion Merck Offer Could Be a Win-Win. (Barrons.com)
Jun-02-25 05:08PM	Merck held talks to buy biotech MoonLake for over $3 billion, FT reports (Reuters) +5.51%
May-27-25 03:33PM	H.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PT (Insider Monkey)
May-15-25 09:55AM	Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet (Zacks)
May-12-25 04:00PM	MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-25-25 04:05PM	MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 (GlobeNewswire)
Apr-23-25 12:52PM	Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
Apr-08-25 03:31AM	MoonLake Immunotherapeutics: A Buy At Dips (Seeking Alpha) -5.59%
Apr-03-25 07:00AM	MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates (GlobeNewswire)
07:00AM	Loading…
Feb-26-25 07:00AM	MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-25-25 09:49AM	Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now? (Insider Monkey)
Feb-23-25 01:33PM	MoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to Analysts (Insider Monkey)
Feb-20-25 12:12PM	MoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy Now (Insider Monkey)
Jan-10-25 07:15AM	MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG (TipRanks)
Jan-08-25 07:00AM	MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody sonelokimab (GlobeNewswire)
Nov-13-24 08:00AM	MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody sonelokimab in patients with active psoriatic arthritis (GlobeNewswire)
Nov-07-24 07:00AM	MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Oct-08-24 09:11PM	Biotechnology Value Fund L.P. Reduces Stake in MoonLake Immunotherapeutics (GuruFocus.com)
Sep-24-24 11:55PM	Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now? (Insider Monkey) -6.36%
Sep-23-24 02:44AM	MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR Stock (Insider Monkey)
Sep-09-24 07:00AM	MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 (GlobeNewswire)
Aug-27-24 08:21PM	MoonLake Immunotherapeutics (MLTX): One of Oppenheimers Top Stock Picks For the Next 12 Months (Insider Monkey)
Aug-07-24 08:00AM	MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 (GlobeNewswire)
Jun-10-24 08:00AM	MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody sonelokimab in Psoriatic Arthritis (GlobeNewswire)
08:00AM	Loading…
May-16-24 08:00AM	MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (GlobeNewswire)
May-07-24 09:02PM	MoonLake Immunotherapeutics Reports Q1 2024 Financial Outcomes (GuruFocus.com)
01:53PM	MLTX Stock Earnings: MoonLake Misses EPS for Q1 2024 (InvestorPlace)
10:15AM	MoonLake Immunotherapeutics Q1 Net Loss Widens (MT Newswires)
08:00AM	MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-10-24 07:00AM	MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions (GlobeNewswire)
Mar-11-24 04:25PM	MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test (Investor's Business Daily)
Mar-10-24 12:00PM	MoonLake announces significant improvements with Nanobody sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day (GlobeNewswire)
Mar-04-24 08:00AM	MoonLake Immunotherapeutics to present MIRA trial data of Nanobody sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 (GlobeNewswire)
Mar-01-24 12:38AM	Insider Sell: CEO Santos da Silva Jorge Sells 123,615 Shares of MoonLake Immunotherapeutics (MLTX) (GuruFocus.com) +5.56%
Feb-29-24 08:00AM	MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10 (GlobeNewswire) -15.09%
Feb-26-24 08:00AM	MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody sonelokimab (SLK) in Hidradenitis Suppurativa (HS) (GlobeNewswire)
Feb-20-24 11:44PM	Insider Sell: CEO Santos da Silva Jorge Sells 60,000 Shares of MoonLake Immunotherapeutics (GuruFocus.com) -7.88%
Jan-11-24 09:55AM	Wall Street Analysts Believe MoonLake Immunotherapeutics (MLTX) Could Rally 26.97%: Here's is How to Trade (Zacks)
Jan-10-24 08:42AM	Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now? (Zacks)
Dec-22-23 03:01PM	CFO Matthias Bodenstedt Sells 100,000 Shares of MoonLake Immunotherapeutics (GuruFocus.com)
Nov-14-23 12:13PM	MoonLake Immunotherapeutics (MLTX) Posts Q3 2023 Results: Clinical Progress Amid Controlled Expenses (GuruFocus.com)
08:00AM	MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-06-23 04:03PM	Why Former Highflier MoonLake Plummeted 29% After A Recent Run (Investor's Business Daily) -29.11% +15.98%
09:46AM	Top-Rated MoonLake Stock Crashes On Mixed Test Results For Arthritis Drug (Investor's Business Daily)
Nov-05-23 11:00AM	MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody sonelokimab in active psoriatic arthritis (GlobeNewswire)
Oct-26-23 10:33AM	12 Best Performing NASDAQ Stocks in 2023 (Insider Monkey)
Oct-20-23 01:22PM	12 Best Performing Biotech Stocks in 2023 (Insider Monkey)
Oct-16-23 04:30PM	MoonLake Immunotherapeutics' Lead Skin Disorder Candidate Continues to Deliver on Best-Efficacy Profile: Analyst (Benzinga) +10.72% -5.20%
04:04PM	Why Top-Notch MoonLake Surged 11% And Almost Broke Out (Investor's Business Daily)
10:41AM	Why Top 1% Biotech MoonLake Just Surged Within Striking Distance Of A Breakout (Investor's Business Daily)
Oct-15-23 09:03AM	MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa (GlobeNewswire)
Oct-11-23 10:15AM	MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress (GlobeNewswire) -7.06%
Oct-04-23 07:01AM	Phase 2 MIRA primary analysis trial results (12-week) for MoonLake's Nanobody sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress (GlobeNewswire)
Sep-27-23 09:24PM	7 Strong Buy Biotech Stocks to Rejuvenate Your Portfolio (InvestorPlace)
Sep-18-23 05:09PM	These 7 Stocks Are Outperforming Nvidia In 2023 (Investor's Business Daily)
Sep-13-23 09:45AM	ACELYRIN (SLRN) Fails to Meet Goal in HS Study, Stock Down 54% (Zacks)
Sep-12-23 04:07PM	The Surprising Acelyrin News That Sent Rival MoonLake, A Top 1% Stock, Soaring 10% (Investor's Business Daily) +9.88%
11:40AM	Why Shares of MoonLake Immunotherapeutics Are Rising Tuesday (Motley Fool)
Sep-06-23 07:00AM	MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11 (GlobeNewswire)
Sep-01-23 02:00PM	Top Growth Stocks for September 2023 (Investopedia) -6.32%
11:30AM	Top Stocks for September 2023 (Investopedia)
Aug-31-23 09:53AM	Palantir downgraded, Shopify upgraded: Wall Street's top analyst calls (The Fly)
08:30AM	The 7 Most Promising Momentum Stocks to Own Now (InvestorPlace)
Aug-16-23 03:12PM	15 Best Performing Stocks in the Last 3 Months (Insider Monkey)
Aug-15-23 07:00AM	Get In on This Skin Disease Drug Before Big Pharma Does (The Wall Street Journal)
Aug-10-23 07:00AM	MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Jul-25-23 08:00AM	MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts (GlobeNewswire)
Jul-14-23 03:38PM	Exclusive-MoonLake Immunotherapeutics explores sale-sources (Reuters) +8.39%
Jul-03-23 09:45AM	MoonLake Immunotherapeutics' (NASDAQ:MLTX) high hedge funds ownership speaks for itself as stock continues to impress, up 11% over last week (Simply Wall St.)
Jun-29-23 02:41PM	Why MoonLake Immunotherapeutics Stock Skyrocketed This Week (Motley Fool)
Jun-28-23 05:00AM	MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares (GlobeNewswire)
Jun-27-23 06:56PM	Why MoonLake Immunotherapeutics Was Such a Healthy Stock Today (Motley Fool) +12.71%
Jun-26-23 04:07PM	Why Mutual Fund Darling And Top 1% Stock MoonLake Just Catapulted To A Record (Investor's Business Daily) +77.55%
04:01PM	MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering (GlobeNewswire)
02:36PM	Why Shares of MoonLake Immunotherapeutics Skyrocketed Monday (Motley Fool)
09:01AM	Lucid Stock Moved Into the Fast Lane, but This Nasdaq Biotech Was Monday's Big Winner (Motley Fool)
Jun-25-23 09:00AM	MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa (GlobeNewswire)
May-26-23 08:50AM	MoonLake Immunotherapeutics (MLTX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-14-23 09:43AM	TipRanks Perfect 10 List: 3 Top-Rated Stocks That Tick All the Right Boxes (TipRanks)
May-12-23 07:45AM	MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
May-11-23 08:32AM	Why MoonLake (MLTX) Might Surprise This Earnings Season (Zacks) -5.45%
May-10-23 08:50AM	Here's Why Momentum in MoonLake Immunotherapeutics (MLTX) Should Keep going (Zacks)
May-03-23 06:45AM	MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply (GlobeNewswire) +7.55%
Apr-24-23 08:50AM	MoonLake Immunotherapeutics (MLTX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks) +10.08%
Apr-19-23 08:16AM	MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today (GlobeNewswire)
Apr-05-23 12:00PM	What Makes MoonLake Immunotherapeutics (MLTX) a New Buy Stock (Zacks) +6.84%
Mar-20-23 07:45AM	MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update (GlobeNewswire) -7.87%
Feb-14-23 01:02PM	Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path (Benzinga) +8.16%
Feb-02-23 08:00AM	MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa (GlobeNewswire)
Dec-14-22 08:00AM	MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis (GlobeNewswire)
Nov-14-22 08:00AM	MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update (GlobeNewswire)
Sep-26-22 10:57AM	FDA Clears MoonLake's Nanobody Study For Arthritis Patients (Benzinga)
08:00AM	MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis (GlobeNewswire)
Jul-26-22 08:00AM	MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH (GlobeNewswire) +13.31%

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Moukheibir Catherine	Director	Jul 03 '25	Option Exercise	0.00	23,500	0	23,500	Jul 07 04:03 PM
Moukheibir Catherine	Director	Jul 03 '25	Sale	48.79	23,500	1,146,565	0	Jul 07 04:03 PM
Moukheibir Catherine	Director	Jul 03 '25	Proposed Sale	48.79	23,500	1,146,595		Jul 03 01:23 PM
BVF PARTNERS L P/IL	Director	Oct 04 '24	Sale	50.00	2,000,000	100,003,200	1,287,768	Oct 08 06:50 PM
Sturge Simon	Director	Oct 04 '24	Sale	53.72	171,000	9,186,120	171,980	Oct 08 04:01 PM

Dollar change -0.0233
Percentage change -2.95	%

IRWD Ironwood Pharmaceuticals Inc daily Stock Chart

Peers: ABBV VRTX ALNY GILD INCY NBIX REGN BIIB BMY EXEL

| Held by: IWM VTI FNDA VXF IWO IBB VTWO SCHA VFVA ISMD

Index	RUT	P/E	-	EPS (ttm)	-0.20	Insider Own	3.74%	Shs Outstand	161.81M	Perf Week	2.02%
Market Cap	124.20M	Forward P/E	2.17	EPS next Y	0.35	Insider Trans	-4.11%	Shs Float	155.76M	Perf Month	20.94%
Enterprise Value	614.80M	PEG	-	EPS next Q	0.03	Inst Own	97.49%	Short Float	4.80%	Perf Quarter	2.33%
Income	-31.41M	P/S	0.39	EPS this Y	1644.75%	Inst Trans	-1.56%	Short Ratio	3.00	Perf Half Y	-79.48%
Sales	317.68M	P/B	-	EPS next Y	102.88%	ROA	-8.20%	Short Interest	7.48M	Perf YTD	-82.67%
Book/sh	-2.06	P/C	1.14	EPS next 5Y	141.01%	ROE	-	52W High	7.11 -89.20%	Perf Year	-88.84%
Cash/sh	0.67	P/FCF	1.58	EPS past 3/5Y	-88.04% -47.49%	ROIC	-12.00%	52W Low	0.53 45.61%	Perf 3Y	-93.67%
Dividend Est.	-	EV/EBITDA	7.16	Sales past 3/5Y	-5.30% -3.89%	Gross Margin	99.38%	Volatility	9.83% 9.35%	Perf 5Y	-92.35%
Dividend TTM	-	EV/Sales	1.94	EPS Y/Y TTM	97.12%	Oper. Margin	26.42%	ATR (14)	0.07	Perf 10Y	-91.98%
Dividend Ex-Date	-	Quick Ratio	3.34	Sales Y/Y TTM	-23.18%	Profit Margin	-9.89%	RSI (14)	53.46	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.34	EPS Q/Q	-779.55%	SMA20	3.66%	Beta	0.33	Target Price	0.95
Payout	0.00%	Debt/Eq	-	Sales Q/Q	-45.05%	SMA50	12.42%	Rel Volume	0.50	Prev Close	0.79
Employees	253	LT Debt/Eq	-	Earnings	May 07 BMO	SMA200	-66.99%	Avg Volume	2.50M	Price	0.77
IPO	Feb 03, 2010	Option/Short	Yes / Yes	EPS/Sales Surpr.	-68.87% -10.36%	Trades		Volume	1,235,867	Change	-2.95%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-15-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-15-25	Downgrade	Jefferies	Buy → Hold
Apr-14-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Sep-09-24	Initiated	Leerink Partners	Market Perform	$5
Aug-08-24	Downgrade	CapitalOne	Overweight → Equal Weight	$12 → $4
Jan-17-24	Initiated	Craig Hallum	Buy	$21
Dec-14-23	Initiated	Wells Fargo	Overweight	$20
Nov-09-23	Initiated	Jefferies	Buy	$21
Sep-28-23	Initiated	JMP Securities	Mkt Outperform	$22
Sep-02-22	Initiated	CapitalOne	Overweight	$15
Apr-22-22	Initiated	Piper Sandler	Overweight	$16
Sep-30-20	Downgrade	Wells Fargo	Overweight → Equal Weight	$14 → $9
Jun-17-20	Initiated	Northland Capital	Outperform	$14
Jul-10-19	Resumed	Credit Suisse	Neutral
Mar-27-19	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Feb-25-19	Upgrade	H.C. Wainwright	Sell → Neutral	$14
Jan-24-19	Upgrade	JP Morgan	Underweight → Neutral
Nov-07-18	Downgrade	JP Morgan	Neutral → Underweight
Nov-07-18	Downgrade	Credit Suisse	Outperform → Neutral
Jul-23-18	Initiated	H.C. Wainwright	Sell	$12.50

Show Previous Ratings

Jun-06-25 11:31AM	Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report? (Zacks) +6.58%
May-08-25 09:55AM	IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates (Zacks) -11.63%
May-07-25 08:20AM	Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -14.55%
07:26AM	Ironwood: Q1 Earnings Snapshot (Associated Press Finance)
07:05AM	Ironwood Pharmaceuticals Reports First Quarter 2025 Results (Business Wire)
10:00AM	Loading…
May-06-25 10:00AM	Vivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
May-05-25 07:15AM	Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-03-25 10:24PM	The 1-Minute Market Report May 4, 2025 (Seeking Alpha)
May-01-25 10:01AM	Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-30-25 04:25PM	Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference (Business Wire)
Apr-28-25 10:25AM	The 1-Minute Market Report April 27, 2025 (Seeking Alpha) +9.23%
Apr-25-25 07:05AM	Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance (Business Wire)
Apr-22-25 04:05PM	Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support (Business Wire) +7.66%
Apr-16-25 01:07PM	Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News (Zacks)
Apr-15-25 09:18AM	Ironwood Shares Tank on Regulatory Update for Apraglutide (Zacks) +11.47%
07:12AM	Loading…
07:12AM	Ironwoods shares sink as FDA demands new trial for lead drug (Pharmaceutical Technology)
Apr-14-25 07:00AM	Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide (Business Wire) -31.48%
Apr-13-25 10:44AM	The 1-Minute Market Report April 13, 2025 (Seeking Alpha)
Apr-10-25 10:49AM	Ironwood Pharmaceuticals: Setting A Strong Foundation For A Return To Growth (Seeking Alpha)
09:25AM	Why Ironwood Pharmaceuticals Inc. (IRWD) Went Down On Thursday? (Insider Monkey)
Apr-01-25 10:28AM	Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar? (Zacks)
Mar-31-25 08:05AM	The 1-Minute Market Report March 30, 2025 (Seeking Alpha)
Mar-27-25 04:05PM	Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing (Business Wire)
Mar-25-25 11:08AM	Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains? (Zacks)
Mar-02-25 12:24PM	Is Ironwood Pharmaceuticals, Inc. (IRWD) the Best Small Cap Pharma Stock to Buy Now? (Insider Monkey)
Feb-28-25 02:14AM	Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Call Highlights: Strong Prescription ... (GuruFocus.com)
Feb-27-25 11:20PM	Q4 2024 Ironwood Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -5.26%
08:15AM	Ironwood Pharmaceuticals (IRWD) Q4 Earnings and Revenues Miss Estimates (Zacks)
07:20AM	Ironwood: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance (Business Wire)
08:13AM	Loading…
Feb-26-25 08:13AM	Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-20-25 04:00PM	Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call (Business Wire)
Feb-05-25 06:28PM	Millrose Properties Set to Join S&P SmallCap 600 (PR Newswire) -8.06%
Jan-29-25 04:05PM	Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future (Business Wire) -38.17%
Jan-18-25 08:20AM	Ozempic, Xtandi among next 15 drugs selected for U.S. price talks (TipRanks)
Dec-20-24 09:15AM	Heres Why Brown Capital Management Small Company Fund Sold Ironwood Pharmaceuticals (IRWD) (Insider Monkey) +14.69%
Nov-26-24 04:01PM	Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference (Business Wire) +5.07%
Nov-13-24 04:01PM	Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference (Business Wire)
Nov-08-24 04:01AM	Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... (GuruFocus.com) +6.44%
Nov-07-24 08:15AM	Ironwood Pharmaceuticals (IRWD) Misses Q3 Earnings Estimates (Zacks) -7.54%
07:20AM	Ironwood: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Ironwood Pharmaceuticals Reports Third Quarter 2024 Results (Business Wire)
Nov-06-24 07:29AM	Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com) +12.25%
Oct-28-24 07:00AM	Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024 (Business Wire)
Oct-24-24 04:00PM	Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call (Business Wire)
Oct-16-24 01:06PM	State Street Corp's Strategic Acquisition of Ironwood Pharmaceuticals Shares (GuruFocus.com)
08:58AM	Is Ironwood Pharmaceuticals, Inc. (IRWD) the Penny Stock with the Biggest Upside Potential According to Analysts? (Insider Monkey)
Oct-09-24 05:36PM	Ironwood Pharmaceuticals Inc (IRWD) Q2 2024 Earnings Call Highlights: Strong LINZESS Demand ... (GuruFocus.com)
Sep-17-24 08:40AM	Implied Volatility Surging for Ironwood (IRWD) Stock Options (Zacks)
Sep-01-24 10:26PM	Ironwood Pharmaceuticals, Inc. (IRWD): The Best Multibagger Penny Stock of 2025? (Insider Monkey)
Aug-29-24 08:41PM	10 Best Multibagger Penny Stocks of 2025 (Insider Monkey) +7.58%
04:01PM	Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference (Business Wire)
Aug-09-24 10:56AM	Ironwood (IRWD) Q2 Earnings & Revenues Fall Shy of Estimates (Zacks)
Aug-08-24 08:15AM	Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q2 (Zacks) -32.61%
07:16AM	Ironwood: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Ironwood Pharmaceuticals Reports Second Quarter 2024 Results (Business Wire)
Aug-01-24 10:01AM	Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q2 Earnings Expected to Decline (Zacks)
Jul-25-24 04:00PM	Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call (Business Wire)
Jul-17-24 08:30AM	Implied Volatility Surging for Ironwood Pharmaceuticals (IRWD) Stock Options (Zacks)
Jul-08-24 07:00AM	Memo Therapeutics AG appoints Paul Carter as Chairperson (GlobeNewswire)
Jun-12-24 07:00PM	Insider Sale: Director Julie Mchugh Sells Shares of Ironwood Pharmaceuticals Inc (IRWD) (GuruFocus.com) -6.27%
Jun-10-24 07:00PM	Insider Sale: Director Catherine Moukheibir Sells 80,000 Shares of Ironwood Pharmaceuticals Inc ... (GuruFocus.com)
May-30-24 04:01PM	Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-21-24 06:00AM	Ironwood Late-Breaker Oral Presentation at Digestive Disease Week Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF) (Business Wire) +5.61%
May-10-24 01:58PM	Ironwood Pharmaceuticals Reports Mixed Q1 2024 Results Amid Key Clinical Advancements (GuruFocus.com)
12:59PM	Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:16AM	Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates (Zacks)
May-09-24 03:59PM	Sector Update: Health Care Stocks Higher Late Afternoon (MT Newswires) -17.00%
01:55PM	Sector Update: Health Care Stocks Gain in Thursday Afternoon Trading (MT Newswires)
01:39PM	Sector Update: Health Care (MT Newswires)
11:57AM	IRWD Stock Earnings: Ironwood Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
09:54AM	Ironwood Pharmaceuticals' Shares Fall After Q1 Swings to a Non-GAAP Loss, Revenue Declines; 2024 Revenue Guidance Cut (MT Newswires)
07:11AM	Ironwood: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Ironwood Pharmaceuticals Reports First Quarter 2024 Results (Business Wire)
May-06-24 04:01PM	Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference (Business Wire)
May-02-24 02:33PM	Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management (Newsfile)
10:01AM	Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q1 Earnings Expected to Decline (Zacks)
May-01-24 07:30AM	Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week 2024 (Business Wire) +6.06%
Apr-30-24 01:16PM	Stock Market Crash Warning: Don't Get Caught Holding These 3 Biotech Stocks (InvestorPlace)
Apr-25-24 04:01PM	Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call (Business Wire)
Apr-21-24 10:39AM	5 Best Low Price Pharma Stocks To Invest In (Insider Monkey)
Mar-28-24 07:30AM	Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD) (Business Wire)
Mar-05-24 01:05PM	Its Time! 3 Failing Biotech Stocks to Sell Right Now (InvestorPlace)
Feb-29-24 04:19PM	Ironwood Pharmaceuticals Ran Up 38% Over Three Months And Just Lost It All (Investor's Business Daily) -37.63%
08:37AM	Why Is Ironwood Pharmaceuticals (IRWD) Stock Down 27% Today? (InvestorPlace)
06:26AM	UPDATE 1-Ironwood's bowel disease treatment meets main goal in late-stage trial (Reuters)
06:08AM	Ironwood says bowel disease treatment meets main goal in late-stage trial (Reuters)
06:00AM	Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF) (Business Wire)
Feb-23-24 07:30AM	Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference (Business Wire)
Feb-16-24 10:15AM	Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:36AM	Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally (Zacks)
Feb-15-24 10:45PM	Q4 2023 Ironwood Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
08:15AM	Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q4 (Zacks)
07:26AM	Ironwood: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance (Business Wire)
Feb-05-24 08:50AM	Ironwood (IRWD) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Feb-01-24 04:01PM	Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call (Business Wire)
Jan-23-24 09:55AM	Wall Street Analysts Think Ironwood (IRWD) Could Surge 37.6%: Read This Before Placing a Bet (Zacks)
Jan-08-24 07:00PM	Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation (Business Wire)
06:00AM	Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance (Business Wire)

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MCCOURT Thomas A	Chief Executive Officer	May 16 '25	Sale	0.58	13,353	7,745	1,147,281	May 20 04:14 PM
Gaskins Tammi L	Chief Commercial Officer	May 16 '25	Sale	0.58	2,563	1,487	242,596	May 20 04:10 PM
MCCOURT Thomas A	Officer	May 19 '25	Proposed Sale	0.59	14,661	8,650		May 16 04:07 PM
Gaskins Tammi L	Officer	May 19 '25	Proposed Sale	0.59	2,814	1,660		May 16 04:05 PM
MCCOURT Thomas A	Chief Executive Officer	Feb 10 '25	Sale	1.76	139,064	244,753	1,160,634	Feb 12 09:00 PM
Silver Ronald	Principal Accounting Officer	Feb 10 '25	Sale	1.76	12,048	21,204	279,655	Feb 12 09:00 PM
Shetzline Michael	SVP, CMO, Head-Res&Drug	Feb 10 '25	Sale	1.76	41,269	72,633	554,007	Feb 12 09:00 PM
John Minardo	Chief Legal Officer	Feb 10 '25	Sale	1.76	38,938	68,531	408,132	Feb 12 09:00 PM
Martini Gregory S.	Chief Financial Officer	Feb 10 '25	Sale	1.76	12,052	21,212	183,810	Feb 12 09:00 PM
MCCOURT Thomas A	Officer	Feb 10 '25	Proposed Sale	1.94	142,454	276,361		Feb 07 04:21 PM
Shetzline Michael	Officer	Feb 10 '25	Proposed Sale	1.94	42,274	82,012		Feb 07 04:20 PM
John Minardo	Officer	Feb 10 '25	Proposed Sale	1.94	39,889	77,385		Feb 07 04:18 PM
Martini Gregory S.	Officer	Feb 10 '25	Proposed Sale	1.94	12,347	23,953		Feb 07 04:17 PM
Davis Andrew	Officer	Dec 27 '24	Proposed Sale	4.00	60,434	241,736		Dec 27 04:43 PM
Davis Andrew	SVP, Chief Business Officer	Nov 18 '24	Sale	4.08	5,360	21,869	284,685	Nov 20 04:05 PM
Emany Sravan Kumar	SVP, COO and CFO	Nov 18 '24	Sale	4.08	11,001	44,884	309,572	Nov 20 04:05 PM
Davis Andrew	Officer	Nov 18 '24	Proposed Sale	4.11	6,090	25,030		Nov 15 04:10 PM
Emany Sravan Kumar	Officer	Nov 18 '24	Proposed Sale	4.11	12,500	51,375		Nov 15 04:07 PM
John Minardo	Chief Legal Officer	Aug 12 '24	Sale	4.27	9,910	42,316	284,661	Aug 14 05:10 PM
Silver Ronald	Principal Accounting Officer	Aug 12 '24	Sale	4.27	3,107	13,267	158,370	Aug 14 05:08 PM
John Minardo	Officer	Aug 12 '24	Proposed Sale	4.05	11,726	47,490		Aug 09 04:05 PM

MLTX

MoonLake Immunotherapeutics

IRWD

Ironwood Pharmaceuticals Inc

Upgrade your FINVIZ experience